Background A light-porous-particle, dry-powder formulation of tobramycin was developed,
using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce
delivery time, and improve patient convenience and satisfaction. We evaluated the safety, …

Rationale Antibiotic therapy for early Pseudomonas aeruginosa infection in patients with
cystic fibrosis (CF) is effective, but the optimal therapeutic regimen and duration for early
treatment remains unclear. The EarLy Inhaled Tobramycin for Eradication (ELITE) study was …

Tobramycin inhalation solution is used to treat chronic Pseudomonas aeruginosa lung
infection in cystic fibrosis (CF) patients. We evaluated the efficacy and safety of a novel, light‐porous
particle, dry‐powder formulation of tobramycin, which was developed to improve delivery …

In patients with cystic fibrosis (CF), respiratory infections with the opportunistic bacterial pathogen
Pseudomonas aeruginosa have a major impact on morbidity and mortality. Aminoglycosides,
especially tobramycin, have been used successfully to combat these infections. …

Background: Immature dendritic cells (DCs) take up antigens in peripheral tissues and, after
antigen processing, mature to efficiently stimulate T cells in secondary lymph nodes. In allergic
airway diseases DCs have been shown to be involved in the induction and maintenance …

Background Various inhaled antibiotics are currently used for treating chronic Pseudomonas
aeruginosa lung infection in cystic fibrosis (CF) patients, however their relative efficacies are
unclear. We compared the efficacy of the inhaled antibiotics tobramycin (TIP, TIS-T, TIS-B), …

The study aimed to determine the efficacy of a safe and well-tolerated dose and regimen of
tobramycin inhalation powder (TIP) on Pseudomonas aeruginosa sputum density in patients
with bronchiectasis. This is a phase II, double-blind, randomised study in bronchiectasis …

… Hanaa Banjar andGerhild Angyalosicontributed to all the sections equally. They reviewed
草案全部提供了重要的有限公司mments for intellectual content and flow. This
study was funded by …Gerhild Angyalosiis in employee of Novartis Pharma AG, Switzerland …

Objective Antibiotic eradication treatment is the standard-of-care for cystic fibrosis (CF) patients
with early Pseudomonas aeruginosa (Pa)-infection; however, evidence from placebo-controlled
trials is limited. Methods This double-blind, placebo-controlled trial randomised CF …

Background: Tobramycin inhalation powder (TIP) was reported to be effective in two Phase
III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas
aeruginosa (Pa). The EDIT study evaluated the efficacy and safety of TIP manufactured by an …